combination therapy with MEKi.
PreclinicalSmall molecule
combination therapy with MEKi. is one of 52 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
166 competitors in Pancreatic Ductal Adenocarcinoma
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Eloxatin
TevaPhase 3
Camptosar
PfizerPhase 3
Taxol
TevaPhase 3
Adrucil
EElorac, Inc.
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ojjaara
GGlaxo Dba Glaxosmithkline
Phase 3
Camptosar
EEastern Cooperative Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMandana Kamgar, MD